What Omix Science does
OMIX Science, founded in 2021 by a team of Harvard-trained scientists and based in Shenzhen (with a Hangzhou presence), develops AI-driven diagnostics for early disease detection built on its TUFEST platform, which combines multi-omics sequencing with machine learning. Its lead product is a blood-based cancer-screening test that the company says requires only 5ml of blood and achieves over 85% sensitivity and 95% specificity in internal validation. OMIX has been designated a 'seed unicorn enterprise' by the Shenzhen government and works with hospital and pharmaceutical partners on precision diagnostics. VCBeat Health and KrASIA report the company closed a Series A of more than RMB 100 million (about $14.6 million) on April 24 2026.
Omix Science is a healthcare tool on Falcoscan. AI-driven early cancer detection from a single blood draw. Falcoscan rates Omix Science with an Opportunity score of 84/100, a Saturation score of 11/100, and a Wrapper-risk score of 9/100. Market signal: rising. Omix Science is founded in 2021, currently at Series_a stage. Pricing: Paid.